<?xml version="1.0" encoding="UTF-8"?>
<ref id="B67-vaccines-08-00273">
 <label>67.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Phillpotts</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Oâ€™brien</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Appleton</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Carr</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Bennett</surname>
    <given-names>A.</given-names>
   </name>
  </person-group>
  <article-title>Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus</article-title>
  <source>Vaccine</source>
  <year>2005</year>
  <volume>23</volume>
  <fpage>1615</fpage>
  <lpage>1623</lpage>
  <pub-id pub-id-type="doi">10.1016/j.vaccine.2004.06.056</pub-id>
  <pub-id pub-id-type="pmid">15694514</pub-id>
 </element-citation>
</ref>
